Belvedere Trading
DMRA

Belvedere Trading’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Belvedere Trading’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-601
Closed -$37.9K – 760
2023
Q2 		$37.9K Buy
+601
New +$32.7K ﹤0.01% 578

Other funds holding DMRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belvedere Trading's DMRA Position: Q3 2023 in Review

Belvedere Trading sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q3 2023, closing a stake of 601 shares — an estimated $37.9K sold.

Belvedere Trading first reported a position in DMRA in Q2 2023 and held it in 1 quarter. The position peaked at $37.9K in Q2 2023. 21 funds tracked by Wall St. Rank hold DMRA as of Q3 2023.

  • Belvedere Trading reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Belvedere Trading sold 601 Damora Therapeutics, Inc. Ordinary Shares shares in Q3 2023, an estimated $37.9K.
  • Belvedere Trading first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q2 2023 and held it in 1 quarter.
  • Belvedere Trading's Damora Therapeutics, Inc. Ordinary Shares position peaked at $37.9K in Q2 2023.
  • 21 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.